Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA.
Perelman School of Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
J Autism Dev Disord. 2023 Aug;53(8):3144-3150. doi: 10.1007/s10803-022-05611-1. Epub 2022 May 28.
Children with autism spectrum disorder (ASD) and intellectual disability (ID)/global delay (GD) frequently have symptoms of attention-deficit/hyperactivity disorder (ADHD). We describe the practice patterns of developmental behavioral pediatricians (DBPs) in the treatment of children with ASD and coexisting ADHD and compare medication classes for children with and without intellectual disability. In bivariate analyses, we compared demographic characteristics, co-occurring conditions, and medication classes for children with and without intellectual disability. Significantly more patients with ID/GD were prescribed α-agonists than patients without ID/GD, but the difference was no longer significant when controlling for age in logistic regression children with ID/GD had more comorbidities and were more likely to be prescribed more than on psychotropic medication. In conclusion, age rather than ID/GD was associated with medication choice.
自闭症谱系障碍(ASD)和智力障碍(ID)/全面发育迟缓(GD)儿童常伴有注意力缺陷多动障碍(ADHD)症状。我们描述了发育行为儿科医生(DBP)在治疗 ASD 合并共患 ADHD 儿童方面的实践模式,并比较了智障和非智障儿童的药物类别。在单变量分析中,我们比较了智障和非智障儿童的人口统计学特征、共患疾病和药物类别。患有 ID/GD 的儿童比没有 ID/GD 的儿童更常被开 α-激动剂,但在 logistic 回归中控制年龄后,这种差异不再显著。患有 ID/GD 的儿童共患疾病更多,更有可能开不止一种精神药物。总之,年龄而不是 ID/GD 与药物选择有关。